Antiviral From Advanced Viral Research Corp. Inhibits CCR5 Cell Receptor For HIV

February 25, 1999

Yonkers, NY, February 25, 1999 - Advanced Viral Research Corp. (OTC BB:ADVR) announced today that its scientists have discovered that its lead antiviral drug, Reticulose, inhibited the production of a key cellular receptor for HIV. Using CD4 positive T-lymphocytes, the scientists found that Reticulose markedly decreased the number of cellular CCR5 receptors. The CCR5 receptor is one of the three most important cell receptors needed by the AIDS virus, HIV, to attach to its target cells and initiate infection.

Interference with the function of the CCR5 cellular chemokine receptor is known to increase the resistance of T-lymphocytes and macrophages to HIV infection. A mutation in the CCR5 gene, especially prevalent in individuals of northern European descent, appears to render these individuals resistant to infection by HIV.

Commenting on this research, Dr. Shalom Z. Hirschman, President and CEO of Advanced Viral Research Corp., stated "The exciting discovery by our scientists that the immunomodulator, Reticulose, interferes with the production of the CCR5 receptor offers a novel approach to the development of therapeutic agents for HIV infection. This new finding may account, in part, for the beneficial effects of Reticulose in the treatment of HIV infected individuals observed in preliminary clinical trials. Furthermore, this new pathway of inhibiting HIV infection suggests that combination therapy with Reticulose may enhance the therapeutic effectiveness of the AIDS cocktails currently in use."

Reticulose is a peptide nucleic acid preparation produced by Advanced Viral Research Corp. which, based on previous history, has been show to be effective against a number of viral diseases. For further information, contact Mark Amster at 954-458-7636.
Note: This news release contains forward-looking statements that involve risks and uncertainties, including risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by ADVR. RETICULOSE is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries

Advanced Viral Research Corp.

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to